Estimation of the hemoglobin glycation rate constant

Masashi Kameyama1, Toshika Okumiya2, Shinji Tokuhiro3, Yoshihisa Matsumura4, Hirotaka Matsui5, Yasuhiro Ono6, Tsuyoshi Iwasaka7, Kazuyuki Hiratani8 & Masafumi Koga9

In a previous study, a method of obtaining mean erythrocyte age ($M_{RBC}$) from HbA1c and average plasma glucose (AG) was proposed. However, the true value of the hemoglobin glycation constant ($k_g$ dL/mg/day), required for this model has yet to be well characterized. Another study also proposed a method of deriving $M_{RBC}$ from erythrocyte creatine (EC). Utilizing these formulae, this study aimed to determine a more accurate estimate of $k_g$. One hundred and seven subjects including 31 patients with hemolytic anemia and 76 subjects without anemia were included in this study. EC and HbA1c data were analyzed, and $M_{RBC}$ using HbA1c, AG and the newly-derived constant, $k_g$ were compared to $M_{RBC}$ using traditional $^{51}$Cr in three patients whose data were taken from previous case studies. A value of $7.0 \times 10^{-6}$ dL/mg/day was determined for $k_g$. $M_{RBC}$ using HbA1c, AG and $k_g$ were found to not be significantly different (paired t-test, $p = 0.45$) to $M_{RBC}$ using traditional $^{51}$Cr. $k_g$ enables the estimation of $M_{RBC}$ from HbA1c and AG.

Abbreviations
AG  Average plasma glucose  
CGM  Continuous glucose monitoring  
DM  Diabetes mellitus  
EC  Erythrocyte creatine  
GA  Glycated albumin  
Hb  Hemoglobin  
HPLC  High performance liquid chromatography  
Hpt  Haptoglobin  
IFCC  International Federation of Clinical Chemistry  
$k_g$  Hemoglobin glycation constant  
MCDP  10-N-methylcarbamoyl-3,7-bis(dimethylamino)phenothiazine  
$M_{RBC}$  Mean erythrocyte age  
NGSP  National Glycohemoglobin Standardization Program  
Ret  Reticulocyte  
SMBG  Self-monitoring of blood glucose.

HbA1c is widely used as both an indicator of glycemic control, as well as a diagnostic index, for diabetes in clinical settings1,2. Hemoglobin glycation is assumed to obey a three compartment model (Fig. 1). The rate constant of the total glycation reaction ($k_g$) is as follows.

$$k_g = \frac{k_1 k_3}{k_2 + k_3} \quad (1)$$

1Department of Diagnostic Radiology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo 173-0015, Japan. 2Department of Biomedical Laboratory Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0976, Japan. 3Department Clinical Laboratory, Kochi Medical School Hospital, Kochi 783-8505, Japan. 4Department of Laboratory Medicine, Kochi Medical School, Kochi 783-8505, Japan. 5Department of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan. 6Department of Internal Medicine, Kouchoukai Takagi Hospital, Fukuoka 831-0016, Japan. 7Preventive Medical Center, Kouchoukai Takagi Hospital, Fukuoka 831-0016, Japan. 8Diabetes Center, Shinseikai Toyama Hospital, Toyama 939-0243, Japan. 9Department of Internal Medicine, Hakucho Central Hospital, Hyogo 661-0953, Japan. *email: kame-tky@umin.ac.jp
Although HbA1c is generally indicative of recent glycemic control over the past 1–2 months, it is known to show reduced correlation to glycemic control status in the presence of diseases which result in a shortened erythrocyte lifespan such as hemolytic anemia.

Erythrocyte creatine (EC) is a good marker that reflects the mean erythrocyte age. We proposed a method that compensates glycated albumin (GA)/IFCC-HbA1c ratio for hemolysis by EC.

We have recently proposed a simple method to obtain mean erythrocyte age \( M_{\text{RBC}} \) from HbA1c and average glucose (AG), which has theoretically derived based on \( \Gamma \)-like function model of erythrocyte lifespan:

\[
M_{\text{RBC}} \simeq \frac{HbA1c}{(1 - \frac{2}{3}HbA1c)kgAG}
\]

(2)

This formula provides meaningful information for the diagnosis of anemia. We estimated \( k_g \) to be \( 6–10 \times 10^{-6} \) dL/mg/day based on past literature. However, a more accurately estimated value of \( k_g \) would provide more useful information.

The relationship between \( M_{\text{RBC}} \) and EC was previously established based on a model and the data from 21 patients, which included EC and \( 51 \text{Cr} \), as following:

\[
M_{\text{RBC}} = -22.84 \log_e EC + 65.83
\]

(3)

This study aimed to determine the accurate value of \( k_g \) from EC-derived \( M_{\text{RBC}} \) and HbA1c.

Results

**Participant characteristics.** Participant demographics are shown in Table 1. All participants had no more than 16% GA. There was no significant difference in the GA of anemic and non-anemic subjects. However HbA1c, Hb, EC and their derivatives showed significant variation between the two groups.

The demographic information on the 3 patients from the previous cases are shown in Table 2.

**Estimation of \( k_g \).** EC derived \( M_{\text{RBC}} \) and \( \frac{iA1c}{1000-\frac{4iA1c}{3iA1c}} \) are shown in Fig. 2. A linear relationship was successfully observed.

\( k_g \) calculated by the two methods outlined previously, for non-hemolytic participants and the entire study population are seen in Table 3. All 4 numbers can be approximated to \( 7 \times 10^{-6} \). Figure 2 shows that data from severe hemolytic patients is less stable. Thus, the value derived from the direct method for calculating \( k_g \) is likely to be the least accurate. Excluding this value as an outlier, the 3 remaining figures were 6.94–6.99 \( \times 10^{-6} \) (average 6.970 \( \times 10^{-6} \)). Therefore, considering significant figures, \( k_g \) can be said to be \( 7.0 \times 10^{-6} \).
Confirmation of derived $k_g$. The $M_{RBC}$ using the derived $k_g$, $7.0 \times 10^{-6}$ and $M_{RBC}$ using $^{51}$Cr half-life are shown in Table 4.

$M_{RBC}$ derived from iA1c were 36.95 ± 5.93, $M_{RBC}$ derived from $^{51}$Cr half-life were 41.29 ± 2.22. Paired $t$-test: $t = -0.9278$; df, 2; $p$ (bilateral), 0.4514. Thus, $M_{RBC}$ derived from iA1c and $M_{RBC}$ using $^{51}$Cr half-life were not significantly different.

Discussion

Based on EC-derived $M_{RBC}$ and HbA1c data, a more accurate value for the constant $k_g$ was obtained. Though $k_g$ was previously determined to be $6–10 \times 10^{-6}$ dL/mg/day, the more accurate value of $7.0 \times 10^{-6}$ improves the usefulness of the proposed model allowing closer approximation of $M_{RBC}$ based on AG and iA1c.

Moreover, the validity of $k_g$ has been confirmed through comparison of $M_{RBC}$ derived from iA1c and $k_g$ with $M_{RBC}$ derived from $^{51}$Cr half-life. Of the three patients with hemolytic anemia and comorbid DM analyzed, data from two patients showed a remarkable correlation with the model derived figures. Data from one patient showed a 1.47 times difference in values however, this may be attributable to the use of SMBG instead of CGM, and the difficulty of standardizing $^{51}$Cr data containing elution.

Variant hemoglobin should be distinguished from hemolysis when $M_{RBC}$ determined by Eq. (2) is low. Glycated variant hemoglobin will exhibit different peaks in HPLC from normal HbA1c, resulting in erroneously low

| Case | Herranz$^{10}$ | Ishii$^{11}$ | Hiratani$^{12}$ |
|------|----------------|-------------|----------------|
| Age/sex | 30F | 72M | 58F |
| Disease | AIHA | AIHA | HSt |
| DM | Type 1 | Type 2 | Type 2 |
| HbA1c (%) | 5.4 | 6.5 | 5.8 |
| GA (%) | – | 26.1 | 23.3 |
| Hb (g/dL) | Normal | 13.5 | 11.5 |
| Ret (%) | Normal | 1.3 | 1.3 |
| Hpt (mg/dL) | Normal | 82 | 58 |

Table 2. Characteristics of three reported patients with latent hemolysis and DM in literature. These patients showed normal Hb, reticulocyte, and haptoglobin. AIHA, autoimmune hemolytic anemia; HSt, hereditary stomatocytosis, DM, diabetes mellitus; GA, glycated albumin; Hb, hemoglobin; Ret, reticulocyte; Hpt, haptoglobin.

Figure 2. Relationship between EC derived $M_{RBC}$ and iA1c/(1000–(2/3)iA1c). Red circles denote non-hemolytic participants and blue circles denote hemolytic patients. Black line denotes regression line through origin.

Table 3. $k_g$ estimation. Results obtained by the direct method are expressed as mean ± standard deviation (SD).
values for HbA1c (some variants show an artefactually high value). It has previously been reported that variant hemoglobin can be detected by the dissociation between HbA1c measured by HPLC and by immunoassay. Moreover, some variant hemoglobins such as Hb Himeji have different \( k_g \) values from normal Hb. In patients with these variant hemoglobins, Eq. (2) is likely to provide a falsely low \( M_{RBC} \).

There are a number of limitations to this study. The data used to calculate a more specific estimate of \( k_g \) contained EC and HbA1c, but lacked CGM data, necessitating the use of 100 mg/dL as an approximation of AG. However, participants were confirmed to be free of DM through GA, an indicator of glycemic control that is independent of mean erythrocyte age, with a cut off of GA no more than 16%. Further study with more complete data including CGM, HbA1c and EC would provide an even more definitive value for \( k_g \). Another limitation is that the value for \( k_g \) derived in this study is totally dependent on Eq. (3) that derives \( M_{RBC} \) from EC. This equation was based on old published data, which used less sensitive and poorly specific chemical methods of measuring creatine which were prone to cross-reactivity with other guanidino compounds. This may reduce the reliability of the system. In contrast, in this study creatine was measured using an enzymatic method which was sensitive and specific to creatine in erythrocytes which uses 10-N-methylcarbamoyl-3,7-bis(dimethylamino) phenothiazine (MCDP), an \( N \)-methylcarbamoyl derivative of methylene blue, with a high molar absorption coefficient (9.6 \( \times \) 10\(^7\) L mol\(^{-1}\) cm\(^{-1}\)).

**Methods**

**Participants.** One hundred and seven subjects including 31 patients with hemolytic anemia and 76 subjects without anemia were included in this study. All samples were prepared and analyzed in accordance with the protocols approved by the institutional committees at Kumamoto University and other collaborating institutions.

Participants with hemolytic anemia were recruited from 115 patients who were older than 20 years old and required laboratory tests including complete blood counts and reticulocyte counts (Ret) for clinical reasons. Those who were suspected of having diabetes mellitus (DM) based on history, a low 1,5-Anhydroglucitol (1,5-AG) value (male, < 14.9 μg/mL; female, < 12.4 μg/mL), or had comorbid liver or renal diseases, were excluded, as liver and renal diseases affect HbA1c and GA. EC, HbA1c, GA, haptoglobin, and other biochemical screening items were measured using the existing plasma samples from these patients. Use of existing plasma samples from anemic patients without written consent was approved by the institutional review board.

Participants without anemia were recruited from medical examination checkup recipients at Takagi Hospital. Those who had anemia, DM, liver disease, renal disease or who were pregnant were excluded to avoid confounding effects on HbA1c or GA value. We provided the healthy volunteers with detailed information about the study, and all participants without anemia provided written informed consent to participate.

**Data interpretation.** EC was measured enzymatically in accordance with a previous report, HbA1c was measured by high performance liquid chromatography (HPLC) method and GA was measured by enzymatic method using albumin-specific protease, ketoamine oxidase, and albumin assay reagent (Lucica GA-L; Asahi Kasei Pharma Co., Tokyo, Japan). HbA1c expressed in International Federation of Clinical Chemistry (IFCC) units (iA1c) was used for calculations in this study. While the National Glycohemoglobin Standardization Program (NGSP) is used to express HbA1c in many clinical research and medical care settings, NGSP is measured by an old standardized method and at the time of conception, HPLC was not able to distinguish true HbA1c from other products. HPLC technology later advanced, however the derived HbA1c value is adjusted to NGSP in the interest of consistency. IFCC provides a strict definition of iA1c as hemoglobin with a glycated valine in the N-terminal \( \beta \)-chain. Thus, iA1c value is preferred value for estimation of hemoglobin glycation.

To acquire iA1c from HbA1c expressed in NGSP unit, we used the following equation:

\[
HbA1c_{\text{NGSP}} \% = 0.0915 \times \text{iA1c (mmol/mol)} + 2.153\% \tag{4}
\]

\[
\iffalse \text{iA1c (mmol/mol)} = 10.93 \times HbA1c_{\text{NGSP}} \% - 23.53 \tag{5}\falso
\]

\( M_{RBC} \) was acquired from EC by the aforementioned Eq. (3).

---

**Table 4.** \( M_{RBC} \) of 3 cases in literature. HbA1c value is different from Table 2. The AG in Herranz and Ishii were calculated from blood glucose values using self-monitoring of blood glucose (SMBG).

| Case         | Herranz\(^{10}\) | Ishii\(^{11}\) | Hiratani\(^{12}\) |
|--------------|------------------|----------------|------------------|
| HbA1c (%)    | 5.8              | 4.9            | 6.0              |
| iA1c (mmol/mol) | 39.9            | 50.0           | 42.3             |
| AG (mg/dL)   | 203              | 148            | 184              |
| iA1c derived (days) \( M_{RBC} \) | 28.7            | 29.6           | 38.1             |
|              | 29.2             | 43.6           | 38.1             |
| \( ^{14} \text{Cr} \text{ half-life (days)} \) | 20              | 20             | 17.8             |
| \( ^{14} \text{Cr} \text{ derived \( M_{RBC} \) (days)} \) | 42.9            | 42.9           | 38.1             |

\( \iffalse \)
An AG value of 100 mg/dL was substituted for plasma glucose values derived using CGM. This number was based on the average AG of non-diabetic participants and the previously reported findings from a study which showed the median AG in healthy subjects to be reported to be 101.0 (96.3–106.0) mg/dL18 and another ADAG (A1c-derived average glucose) study which found that the AG of the non-diabetic group of their study was similarly 100 mg/dL19,20.

\[ M_{RBC} \]

was also determined using \(^{51}\text{Cr}\) half-life. As the reference range for \(^{51}\text{Cr}\) half-life was described as 28–30 days10, 30 ± 5 days11, and 26–40 days12, \(M_{RBC}\) was calculated by multiplying \(^{51}\text{Cr}\) half-life and 2.14 (= 60/28), 60 days being the normal value for \(M_{RBC}\).

**Data analysis.**  \(EC\) and \(M_{RBC}\) data were analyzed using a spreadsheet software, Excel 365 (Microsoft Corporation, Redmond, WA, USA).

**Estimation of \(k_g\).** The following two methods were used to estimate \(k_g\). The slope method—the following Eq. (6) derived from Eq. (2) shows that the slope of the line connecting a point and the origin is \(k_g\) AG.

\[
\frac{iA1c}{1000 - \frac{3}{2}iA1c} = k_g \times AG
\]

Estimating the slope of the regression line through the origin by the least square model:

\[
\frac{n \sum x_i y_i}{\sum x_i^2} = k_g \times AG
\]

where \(x_i, y_i\) are \(M_{RBC}\) and \(iA1c\), respectively.

The direct method—the \(k_g\) of each participant was calculated by the following equation:

\[
k_g = \frac{iA1c}{(1000 - \frac{3}{2}iA1c)M_{RBC}AG}
\]

Then, average and standard deviation of each \(k_g\) was calculated.

**Confirmation of derived \(k_g\).** The method of obtaining \(M_{RBC}\) from AG and \(iA1c\) was applied to data from three patients with latent hemolysis who were presented in a previous case studies10–12.

Data of Herranz10 and Ishii11 showed changes in HbA1c during the course of the study. Therefore, \(M_{RBC}\) was calculated separately for each period. For the Ishii case11, AG was calculated by averaging self-monitoring of blood glucose (SMBG) data for each period. The Hiratani study12 examined \(^{51}\text{Cr}\) erythrocyte lifespan measurement during hospitalization in Oct 1999 and CGM in Feb 2016. While HbA1c and plasma glucose concentrations fluctuate routinely, RBC lifespan remain comparatively constant, especially when influenced by a certain diseases (stomatocytosis). Furthermore, supply of \(^{51}\text{Cr}\) was ceased in Japan in 2015 and thus it can no longer be used to study erythrocyte lifespan.

**Ethical approval and consent to participate.** The work was conducted in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan and conformed to the Helsinki Declaration. All samples were prepared and analyzed in accordance with the protocols approved by the institutional committees at Kumamoto University and other collaborating institutions.

**Data availability**
The data supporting the findings can be obtained on reasonable request to the corresponding author.

Received: 4 July 2020; Accepted: 3 December 2020
Published online: 13 January 2021

**References**
1. Koenig, R. J. et al. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. *N. Engl. J. Med.* **295**, 417–420. [https://doi.org/10.1056/NEJM197608192950804](https://doi.org/10.1056/NEJM197608192950804) (1976).
2. American Diabetes Association. Glycemic targets in Standards of Medical Care in Diabetes—2017. *Diabetes Care* **40**, S48–S56. [https://doi.org/10.2337/dci17-0009](https://doi.org/10.2337/dci17-0009) (2017).
3. Panzer, S. et al. Glycosylated hemoglobins (GHB): an index of red cell survival. *Blood* **59**, 1348–1350 (1982).
4. Okumiyama, T. et al. Sensitive enzymatic assay for erythrocyte creatine with production of methylene blue. *Clin. Chem.* **44**, 1489–1496 (1998).
5. Koga, M. et al. HbA1c adjusted by erythrocyte creatine is a useful glycemic control indicator in patients with hemolysis. *Clin. Biochem.* **73**, 77–81 (2019).
6. Kameyama, M., Takeuchi, S. & Ishii, S. Steady-state relationship between average glucose, HbA1c and RBC lifespan. *Biochem. Clin. Pharmacol.* **59**, 111–117. [https://doi.org/10.1007/s10528-016-9470-4](https://doi.org/10.1007/s10528-016-9470-4) (2016).
7. Shrestha, R. P. et al. Models for the red blood cell lifespan. *J. Pharmacokinet. Pharmacodyn.* **43**, 259–274. [https://doi.org/10.1007/s10928-016-9470-4](https://doi.org/10.1007/s10928-016-9470-4) (2016).
8. Fehr, J. & Knob, M. Comparison of red cell creatine level and reticulocyte count in appraising the severity of hemolytic processes. *Blood* **53**, 966–976 (1979).
9. Kameyama, M., Koga, M. & Okumiyama, T. A novel method for calculating mean erythrocyte age using erythrocyte creatine. *Aging (Albany NY)* **12**, 8702–8709 (2020).
10. Herranz, L., Grande, C., Janez, M. & Pallardo, F. Red blood cell autoantibodies with a shortened erythrocyte life span as a cause of lack of relation between glycosylated hemoglobin and mean blood glucose levels in a woman with type 1 diabetes. Diabetes Care 22, 2085–2086. https://doi.org/10.2337/diacare.22.12.2085 (1999).

11. Ishii, C., Tané, N., Negishi, K. & Katayama, S. A case of type 2 diabetes who showed discrepancy between plasma glucose and HbA1c due to latent autoimmune hemolytic anemia (in Japanese). J. Jpn. Diabetes Sci. Soc. 44, 157–160. https://doi.org/10.11213/tonyobyo1958.44.157 (2001).

12. Hiratani, K., Natazuka, T., Suemori, S., Wada, H. & Koga, M. A case of stomatocytosis in a type 2 diabetic patient accompanied with falsely low HbA1c levels due to latent hemolysis (in Japanese). J Japan Diab Soc 59, 719–725. https://doi.org/10.11213/tonyobyo.59.719 (2016).

13. Miyazaki, A., Kohzuma, T., Kasayama, S. & Koga, M. Classification of variant forms of haemoglobin according to the ratio of glycated haemoglobin to glycated albumin. Ann. Clin. Biochem. 49, 441–444. https://doi.org/10.1258/acb.2012.011192 (2012).

14. Koga, M. et al. Aldimine formation reaction, the first step of the maillard early-phase reaction, might be enhanced in variant hemoglobin, Hb Himeji. Ann. Clin. Lab. Sci. 45, 643–649 (2015).

15. Kashiwagi, A. et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol. Int. 3, 8–10. https://doi.org/10.1111/j.2040-1124.2012.00207.x (2012).

16. Kouzuma, T., Usami, T., Yamakoshi, M., Takahashi, M. & Imamura, S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin. Chim. Acta 324, 61–71. https://doi.org/10.1016/s0009-8981(02)00207-3 (2002).

17. Hodelz, W. et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin. Chem. 50, 166–174. https://doi.org/10.1373/clinchem.2003.024802 (2004).

18. Tsujino, D. et al. Daily glucose profiles in Japanese people with normal glucose tolerance as assessed by continuous glucose monitoring. Diabetes Technol. Ther. 11, 457–460. https://doi.org/10.1089/dia.2008.0083 (2009).

19. Malka, R., Nathan, D. M. & Higgins, J. M. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. Sci. Transl. Med. 8, 359ra130. https://doi.org/10.1126/scitranslmed.aad9304 (2016).

20. Nathan, D. M. et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 31, 1473–1478. https://doi.org/10.2337/dc08-0545 (2008).

Acknowledgements
The authors would like to thank Ms. Natalie Okawa for English language editing of this manuscript.

Author contributions
M.Ka. contributed to study design, discussing the results, statistical analysis, project administration, the figures and initial draft manuscript preparation. T.O. contributed to organization of data acquisition, measurement of erythrocyte creatine, and advised the project. M.Ko. contributed to the conceptualization, study design, data curation, discussing the results, statistical analysis, and project administration. All the authors discussed the project and have read and approved the final manuscripts.

Competing interests
M.Kameyama received research funds from Fujifilm Toyama Cemical Co., Ltd., Nihon Medi-Physics Co. Ltd., and Daiichi-Sankyo Co., Ltd. TO received research funding from Asahi Kasei Pharma.

Additional information
Correspondence and requests for materials should be addressed to M.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021